Jefferies Financial Group Inc. Acquires New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV)

Jefferies Financial Group Inc. purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 40,000 shares of the company's stock, valued at approximately $473,000.

Several other institutional investors have also modified their holdings of the company. Barclays PLC increased its stake in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Elevate Capital Advisors LLC purchased a new position in Roivant Sciences in the 4th quarter valued at about $2,116,000. Thompson Siegel & Walmsley LLC grew its stake in Roivant Sciences by 10.1% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after purchasing an additional 51,705 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at about $995,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insider Activity

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 315,522 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the transaction, the chief operating officer now owns 959,457 shares in the company, valued at $10,611,594.42. The trade was a 24.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,223,959 shares of company stock valued at $13,420,035 over the last ninety days. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Trading Up 1.8%

Shares of Roivant Sciences stock traded up $0.20 during trading on Tuesday, reaching $11.04. The company's stock had a trading volume of 4,631,337 shares, compared to its average volume of 5,580,222. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a 50-day moving average price of $10.51 and a two-hundred day moving average price of $11.07. The stock has a market capitalization of $7.88 billion, a P/E ratio of -73.60 and a beta of 1.23.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.